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Follicular lymphoma (FL) is the most common indolent lymphoma.
It is biologically characterized by the proliferation of follicle centre B cells with translocation t(14;18) and the consequent overexpression of bcl2, as well as recurrent mutations in epigenetic regulators. 1 Clinically, it is diagnosed at a median age of 61 years and most frequently at an advanced stage. 2 When at such stage, whether treatment should or should not be administered (and what regimen) depends on several factors, including tumour burden, patient age and comorbidity as well as patient preference and institutional tradition. This is due to advanced-stage FL being slow growing and
incurable, yet very sensitive to radiotherapy (RT) and immunochemotherapy (ICT), with which good responses and prolonged survival are generally obtained. 3 About 30% of FL are diagnosed at a localized stage. 2, 4, 5 The prognosis of localized-stage FL is excellent regardless of the therapeutic strategy. However, localized-stage FL, particularly stage I FL, are often excluded from clinical trials in FL 6, 7 rendering the evidence thence derived not applicable to these patients. Indeed, high-quality evidence for the treatment of localized-stage FL is generally lacking. Conversely, guidelines are very precise in their recommendations. External-beam RT applied to the involved field(s) should be employed, as localized-stage FL is considered curable with this strategy. However, despite these recommendations, publications in recent years have shown that RT is not used in a significant proportion of these patients.
The present manuscript attempts to present the existing concerns with the available evidence on localized-stage FL, as well as to provide an overview of the evidence supporting each of the currently available therapeutic options for localized-stage FL.
| MATERIAL S AND ME THODS
We conducted a systematic review of the treatment of localizedstage FL by means of the PubMed MeSH terms "Follicular lymphoma" and "treatment" in combination with "localized stage," "early stage" and "limited stage." Abstracts from the most recent meetings of the American Society of Hematology (ASH) and International
Conference on Malignant Lymphoma (ICML) were also searched.
Reference lists from the selected studies as well as review articles and editorials were also read and their articles were considered for potential inclusion. While the search had no year restrictions, for the manuscript we preferentially selected publications from the past 10 years, not excluding relevant studies published earlier. Additional searches, particularly concerning imaging and radiation toxicity, were also carried out, albeit in a non-systematic fashion.
| S HORTCOMING S OF THE E XIS TING DATA
As localized-stage FL is a rare entity, there are a very limited number of large studies published in the modern era (starting with the introduction of rituximab, but also with gradually decreasing fields and doses of radiation). Furthermore, given its indolent course, these studies often do not have a long enough follow-up and publications from before the modern era are required to get a glimpse of the very long-term outcomes, even if the long-term survival with (and toxicity of) modern-day treatments may differ significantly from those employed then. Indeed, the biological, technological and therapeutic improvements that have taken place in the last years and decades render the applicability of older studies to the present-day questionable.
| Diagnosis of FL
In 2001, the first World Health Organization (WHO) classification of lymphoid neoplasms was published. 8 It integrated knowledge of disease biology that was previously unknown and improved on the previous systems, such as the Rappaport, Working Formulation, Kiel or the REAL classifications. 9 Although the diagnosis of FL can generally be inferred from those made under these other systems, the process is not perfect and becomes complex with the oldest classifications. Similarly, studies (both before and after the WHO classification) may include a variety of indolent (not only follicular) or even higher grade lymphomas, further complicating comparisons with modern-day studies (unless subgroup analyses were carried out).
Finally, even in the present day, some studies include only grade 1-2 FL, while others include also grade 3a, perhaps reflecting existing discrepancies in the conception of grade 3 FL by different scientific bodies. 10 Although the prognostic impact of histological grade is still uncertain, at least one large study in localized-stage FL found a worse prognosis for grade 3a FL. 
| Diagnosis of localized stage
According to current consensus, 12 a modified Ann Arbor system should be used to stage non-Hodgkin lymphoma (NHL). "Localized They were largely abandoned with the advent of computed tomography (CT), which has been the pillar of staging for some decades.
In the last few years, positron-emitting tomography/computed tomography (PET/CT) has become the imaging technique of choice for staging. 12 It has shown improved sensitivity over CT scans, in particular for the diagnosis of early-stage disease, where 44% to 62% of patients can be upstaged. 24, 25 Therefore, even though a large study found that PET-staged did not have better PFS than non-PET-staged patients, 26 the changing sensitivity derived from evolving staging procedures needs to be kept in mind when considering the proportion of patients considered curable, particularly in studies carried out before CT.
Similarly, bone marrow (BM) involvement needs to be ruled out by means of a bone marrow biopsy in order to diagnose localizedstage FL. While often done, most retrospective series report some degree of non-compliance. 5 
| Radiotherapy field and dose
As previously alluded to, all aspects of RT have evolved over the past decades. Concerning radiation dose, large doses (up to 50 Grays
[Gy]) have been used in the past but two randomized studies 31, 32 have established that, for low-grade lymphomas, 24 Gy (in 12 fractions) are as effective as 36 Gy, and more effective than 4 Gy, for local disease control.
The radiation field has been gradually narrowed, based on stud- 
| Endpoints and statistical considerations
Several endpoints are commonly used in NHL. While all are informative, they provide different information. 36 The most relevant outcome from the patient's standpoint is OS but this may take a long time to assess, particularly in localized-stage FL. Furthermore, the results of any one therapy may be difficult to gauge as they may be concealed by effective salvage options. Contrary to OS, progression-free survival (PFS), which may more accurately reflect the results of any one therapy, is somewhat subjective as it requires specifically dating progression of lymphoma, which is a continuous process and which may depend on factors such as the frequency of surveillance imaging. Finally, it is essential to note that some studies, particularly published before modern consensus, 36 have defined the same endpoint (usually PFS) differently (for instance, not considering death due to causes other than lymphoma in the endpoint 11, 14, 33, 37 ), making direct comparisons between studies unwise, especially
given the high non-lymphoma related mortality in localized-stage FL. 14, 17, 18, 20, 22, 23, 38 When citing specific results from studies in this manuscript, we have tried to conform to current terminology 36 whenever possible.
Also due to the high non-lymphoma-related mortality, the as- 
| Observation
This strategy, consisting of withholding treatment in asymptomatic patients, is well supported in advanced low-tumour burden disease, 
| Systemic therapy
To the best of our knowledge, the use of systemic therapy alone has not been explored in any RCT in localized-stage FL. There is, furthermore, no support for this option in retrospective studies from the pre-modern era. However, with the arrival of immunotherapy (largely, rituximab), some patients are receiving rituximab or rituximab-containing regimens 26 despite the lack of evidence or expert support for this option. 3, 45 This is most likely due to the efficacy and tolerability of these regimens in advanced disease. In stage I patients from the NLCS, Friedberg et al, 26 reported a longer PFS with ICT than with RT. However, the NLCS is an observational study,
ICT may be more effective but it is also more toxic than RT and no difference in OS was observed, so systemic therapy alone cannot be recommended for localized-stage disease even though the results predictably show sustained remissions with those strategies.
Two retrospective studies carried out in the modern era 46,47 have compared RT alone vs RT plus rituximab vs rituximab alone. Both studies have found better PFS with the two strategies containing rituximab (and one of them also found a trend for an increased OS 46 ) but the RT arm performed worse than in most classical series (with a median PFS of 2 years in one 46 and a 3-yr PFS probability of 57% in the other 47 ). Similarly, a third study 48 found rituximab-containing regimens to be associated with longer PFS than any of the alternatives, including RT, although once again RT showed worse results than expected based on older and larger trials, which the authors hypothesize could be due to referral bias. Other regimens, such as RCHOP alone 49 or radioimmunotherapy with 90-Y-Ibritumomab, 50 have also been tried in small single-centre studies but would generally not be recommended outside of clinical trials. 
| Radiation therapy
| Evidence from the pre-modern era
Initial randomized trials testing RT alone (often with extended fields and higher doses) vs CM usually included a broad array of histologies, both high grade and low grade. 28, [51] [52] [53] [54] Only one of these studies (before the advent of immunotherapy) found an improvement in relapse-free survival in low-grade histologies 28 and none found an improvement in OS (although the studies were arguably not powered to detect it). To our knowledge, only one study included only patients with low-grade lymphoma 55 and it found no difference in any efficacy endpoint with CM (RT plus chlorambucyl) over RT alone. A large retrospective series from the pre-modern era 15 similarly showed no difference in freedom from relapse between the RT only (60% IF, median dose 36.7 Gy) and CM with a variety of regimens (largely CHOP).
Retrospective series of FL patients in the pre-modern era show a remarkable consistency in the specific efficacy results, with about 50% of patients remaining disease-free at 10 years (Table 1 shows the time to progression and OS in studies using RT for the treatment of localized-stage FL) as well as in the existence of a plateau, with relapses being rare beyond 10 years (although these rare late relapses are almost universal in large studies with long follow-up 11, 14, 16, 23, 34 
| Evidence from the modern era
Two randomized trials have established that 24 Gy is the current patients suffered in-field relapses. The other study, 58 including 91 stage I patients, found a very similar 5-yr PFS probability (73%) but 5 of 19 relapsing patients relapsed within the radiation field (with a short median time to relapse of 17 months, including 6 patients relapsing within a year). This high rate of in-field relapse is in contrast to most trials, which reveal in-field relapses to be very rare (<1%-2%). 5, 11, 18, 22, 54, 57, 59 Some series have found somewhat higher rates, [13] [14] [15] 33, 34 although at least two studies found local relapse to be strongly dependent on tumour bulk. 14,34 A prospective non-randomized trial 60 found that a major factor in relapse risk, particularly in-field relapse, were dose deviations, regardless of radiation field.
Concerning safety, the two aforementioned randomized trials 31,32 established in a prospective fashion the short-term safety profile of RT. In one of the studies, 32 adverse events (AE) of grade 3 or above were seen in only 2.8% of patients treated with 24 Gy, while the other 31 showed that, even the most common grade 2 or 3 acute toxicity (mucositis), occurred in only 11% of cases. Due to the relatively short follow-up, data on secondary malignancies would not be complete, although such toxicity is entirely dependent on the radiation field and anatomic site and, therefore, the results of these trials would be hard to apply to any individual patient. Data from the SEER registry suggests a mild increase in secondary cancers in RTtreated patients in the longer term 61 but there is no data concerning the RT regimens administered in these studies. The incidence of secondary cancer in smaller series from one or a few institutions in largely RT-treated patients is not high and may not be no greater than in the general population.
14,15,22,23
| Combined modality
The rationale for CM is clear given that half of patients with localizedstage disease relapse and, as mentioned, most of them do outside the radiation field, suggesting that localized-stage FL is commonly already spread (even if undetectably) at the time of diagnosis.
| Evidence from the pre-modern era
As mentioned, randomized trials from the pre-modern era found no advantage (in terms of OS) for CM over RT alone, 28 
| Evidence from the modern era
One of the most interesting RCTs (NCT00115700) in FL is being Our group conducted a retrospective study comparing systemic therapy vs RT vs CM in 130 patients from both the pre-modern and the modern eras and also found an increased time to progression with CM. 63 Table 2 shows the characteristics and results of studies including immunotherapy. Overall, then, modern-day CM appears to be more efficacious than RT for disease control. However, the added benefit should overcome the potential added toxicities. Rituximab is relatively non-toxic, but it carries a small risk of infusion reactions, symptomatic neutropenia, hepatitis B virus reactivation or progressive multifocal leucoencephalopathy. RCVP, although generally well tolerated, is more toxic, with a non-negligible risk of symptomatic neutropenia. 6, 59 A potentially more severe downside of this particular combination is that RT and chemotherapy (particularly alkylating agents) could have synergistic (or at least, additive) carcinogenic effects. 64, 65 However, the referenced studies were conducted with older RT and chemotherapy regimens, which are likely more toxic than those currently in use. 
| HIS TOLOG IC AL TR ANS FORMATION
Although not as much as in the pre-modern era, HT is still associated with decreased survival in patients with FL. 66 In patients with localized-stage FL treated with RT the incidence of HT is between 6% and 13% (with follow-ups often around 10 years or longer) and with a percentage of patients relapsing as HT of 11%-21% (Table 3 ), which appears lower than in advanced-stage FL, both in the premodern as well as the present era. [66] [67] [68] Importantly, HT appears to occur quite late in localized-stage FL, with a median time to transformation of 3.6-5.9 years, 17,69 which may be a good prognostic factor. 68 Survival after HT was notably better in patients treated in the modern era (3-yr PFS after HT 78% vs 15% 69 ), in accordance with what has been found in advanced-stage disease. 66 HT in localizedstage FL may be lower in patients treated with rituximab, 22, 59 which would also be consistent with a recent report in FL more broadly. 70 
| LO C ALIZED E X TR ANODAL FL
Extranodal involvement in FL (other than the BM) is infrequent and, when present, is often due to secondary spread. Primary extranodal FL is a very rare entity. In accordance with that, the best evidence available comes from large case series collected over decades and including multiple histologies. 56, [71] [72] [73] [74] Specific subanalyses of FL included in each of these large series include less than 50 cases. Generally, most patients are treated with RT-containing strategies but depending on the site, other strategies are also used to a greater or lesser degree; in cutaneous FL, RT alone was often the treatment modality of choice while in FL of the breast, surgery and/or systemic treatment were commonly added. With these therapeutic strategies, the results obtained were different depending on the site, although they generally appeared better than one would expect for a cohort of patients with advanced FL diagnosed during the same time period. Generally, and based on the very limited data available, extranodal cutaneous FL, the most common extranodal form, is also the one with the best prognosis. 56 
| CURRENT TRE ATMENT OF LO C ALIZED -S TAG E FL
In line with the guidelines, complete staging with a BM biopsy and whole body imaging (preferably PET/CT nowadays) is an essential first step and RT alone should be considered the standard treatment of choice in most cases where all involved nodes can be encompassed in a radiation field. 3, 75 This is based a well-documented potential for a cure with a low toxicity cost. More specifically, and based on the two randomized trials presented above, 31, 32 
| PER S PEC TIVE S FOR THE NE AR FUTU RE
In the upcoming years, longer follow-up (and a publication) from the aforementioned TROG trial is expected. A benefit in terms of OS would be practice-changing, although this appears unlikely given the good and prolonged responses to salvage options currently available. If a difference in PFS is confirmed, CM with a low-toxicity regimen and RT may become two similarly valid options. We do not expect regimens not including RT to be recommended.
Survival curves and causes of death from the trial by the TROG will also provide detailed information on the curability of localizedstage FL and the causes of death (including secondary cancers) of patients treated in the present day. While some series have already reported on that issue, only one was prospective 22 and it was not an RCT. The TROG trial will be able to show whether patients treated with CM are more likely to be cured or whether, despite the longer PFS, the plateaus occur at the same height. better PFS in their recent preliminary analysis, which could be confounded by the use of rituximab. Most importantly, although many years will still be needed, we will learn whether PET/CT-staged patients are more likely to be cured (due to a better selection of patients with limited-stage disease).
Other tools will also be employed to try to rule out undetected systemic involvement. The use of BCL2/IGH has so far not offered results that may be used to guide therapy, with small studies 29, 30 show- 
| CON CLUS ION
A minority of patients with FL are diagnosed at a localized stage.
Rigorous staging is essential for a correct diagnosis. Once the diagnosis is established, prognosis is very good, particularly for nonbulky limited-stage patients, regardless of the strategy employed.
Therefore, the gains obtained with any one of them over any other are likely to be small and there should be an exhaustive examination of long-term toxicity. Accordingly, patients' preferences are particularly relevant. However, for the majority of patients, RT is the standard while awaiting more mature results of CM with low-toxicity regimens.
In this regard, it is worrying that most studies coincide in the low percentage of patients that do receive RT. At a time when most of the attention is centred on advanced-stage disease, targeted drugs and the subset of FL patients with a poor prognosis, those with the best prognosis appear not to be receiving the most evidence-based care.
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